Deverra Therapeutics, Inc., a leading clinical-stage company developing therapeutic allogeneic off-the-shelf cord-blood derived therapeutics has entered into a manufacturing service agreement with the Cleveland Cell Therapy Incubator (CCTI), a subsidiary of the Cleveland Cord Blood Center.
For CCTI, this is an important opportunity to establish itself in the rapidly growing field of cell therapy manufacturing for novel treatments of cancer and other life-threatening diseases.
CCTI will be the production hub for clinical-grade expanded cord blood progenitors and immune cells using Deverra’s proprietary manufacturing platforms to support Deverra’s FDA-approved clinical studies.
The collaboration will extend to using these supplies for the manufacture of Deverra’s products at CCTI’s facility, providing flexibility for product sourcing to expand manufacturing.